Dimethyl Fumarate

Catalog No.S2586 Synonyms: DMF,Tecfidera,BG-12

For research use only.

Dimethyl fumarate (DMF,Tecfidera,BG-12) is the methyl ester of fumaric acid, used to treat people with relapsing forms of multiple sclerosis. Dimethyl fumarate is a nuclear factor (erythroid-derived)-like 2 (Nrf2) pathway activator and induces upregulation of antioxidant gene expression.

Dimethyl Fumarate Chemical Structure

CAS No. 624-49-7

Selleck's Dimethyl Fumarate has been cited by 9 Publications

1 Customer Review

Purity & Quality Control

Choose Selective Nrf2 Inhibitors

Biological Activity

Description Dimethyl fumarate (DMF,Tecfidera,BG-12) is the methyl ester of fumaric acid, used to treat people with relapsing forms of multiple sclerosis. Dimethyl fumarate is a nuclear factor (erythroid-derived)-like 2 (Nrf2) pathway activator and induces upregulation of antioxidant gene expression.
In vitro

Dimethyl fumarate causes short-lived oxidative stress, which leads to increased levels and nuclear localization of the transcription factor nuclear factor erythroid 2-related factor 2 and a subsequent increase in glutathione synthesis and recycling in neuronal cells. [1] Dimethyl fumarate inhibits dendritic cell (DC) maturation by reducing inflammatory cytokine production (IL-12 and IL-6) and the expression of MHC class II, CD80, and CD86. Dimethyl fumarate impairs nuclear factor κB (NF-κB) signaling via reduced p65 nuclear translocalization and phosphorylation. Dimethyl fumarate inhibits maturation of DCs and subsequently Th1 and Th17 cell differentiation by suppression of both NF-κB and ERK1/2-MSK1 signaling. [2] Dimethyl fumarate inhibits TNF-alpha-induced nuclear entry of NF-kappaB in rat heart endothelial cells (RHEC). [3] Dimethyl fumarate, an immune modulator and inducer of the antioxidant response, suppresses HIV replication and neurotoxin release. Dimethyl fumarate attenuates CCL2-induced monocyte chemotaxis, suggesting that Dimethyl fumarate could decrease recruitment of activated monocytes to the CNS in response to inflammatory mediators. [4]

Assay
Methods Test Index PMID
Western blot NRF2 / IRP2 / FBXL5 / FTH1 / FTL 28289076
In vivo

Dimethyl fumarate inhibits nuclear entry of NF-kappaB in RHEC and reduces myocardial infarct size after ischemia and reperfusion in rats in vivo. [3] Dimethyl fumarate oral administration is shown to upregulate mRNA and protein levels of Nrf2 and Nrf2-regulated cytoprotective genes, attenuate 6-OHDA induced striatal oxidative stress and inflammation in C57BL/6 mice. [5]

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 144.13
Formula

C6H8O4

CAS No. 624-49-7
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles COC(=O)C=CC(=O)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04756687 Completed Drug: Dimethyl fumarate Multiple Sclerosis|Multiple Sclerosis Relapsing-Remitting Biogen March 10 2021 --
NCT04221191 Recruiting Drug: Dimethyl Fumarate|Other: PSP Multiple Sclerosis Relapsing-Remitting Biogen August 19 2019 --
NCT03526224 Completed Drug: Dimethyl Fumarate|Drug: Teriflunomide Tecfidera|Teriflunomide University at Buffalo June 14 2018 --
NCT02969304 Completed Drug: dimethyl fumarate Multiple Sclerosis Biogen December 30 2016 --
NCT02461069 Completed Drug: Dimethyl fumarate Multiple Sclerosis Relapsing-Remitting University Hospital Muenster|Biogen May 6 2015 Phase 4
NCT02736279 Unknown status Drug: Dimethyl fumarate Multiple Sclerosis Virginia Simnad|Biogen|EvergreenHealth May 2015 --

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Dimethyl Fumarate | Dimethyl Fumarate ic50 | Dimethyl Fumarate price | Dimethyl Fumarate cost | Dimethyl Fumarate solubility dmso | Dimethyl Fumarate purchase | Dimethyl Fumarate manufacturer | Dimethyl Fumarate research buy | Dimethyl Fumarate order | Dimethyl Fumarate mouse | Dimethyl Fumarate chemical structure | Dimethyl Fumarate mw | Dimethyl Fumarate molecular weight | Dimethyl Fumarate datasheet | Dimethyl Fumarate supplier | Dimethyl Fumarate in vitro | Dimethyl Fumarate cell line | Dimethyl Fumarate concentration | Dimethyl Fumarate nmr